X0206 3 2022-11-16 0 0001638287 NeuroBo Pharmaceuticals, Inc. NRBO 0000886982 GOLDMAN SACHS GROUP INC 200 WEST NEW YORK NY 10282 0 0 1 0 0000769993 GOLDMAN SACHS & CO. LLC 200 WEST STREET NEW YORK NY 10282 0 0 1 0 Common Stock 1220502 I See Footnotes This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. On November 16, 2022, the Reporting Persons experienced an increase in their beneficial ownership of Neurobo Pharmaceuticals, Inc. (the "Issuer") to above 10% of the outstanding Common Stock. On November 17, 2022, the Reporting Persons experienced a decrease in their beneficial ownership that reduced their beneficial ownership to below 10% due to a reduction in excess securities borrows. The Common Stock of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group. /s/ Jamison Yardley, Attorney-in-fact 2022-11-22 /s/ Jamison Yardley, Attorney-in-fact 2022-11-22